OR WAIT 15 SECS
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India.
Mylan announced on May 12, 2020 that it is collaborating with Gilead Sciences to supply investigational antiviral remdesivir for the treatment of COVID-19.
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India, according to a press release. Additionally, Mylan will work to develop a bioequivalent version of remdesivir and its own active pharmaceutical ingredient for sterile powder lyophilized vials for administration of the medicine by intravenous infusion.
"The unprecedented development timeline at Mylan is a direct reflection of the investments we've made to build a first-class, global research and manufacturing platform, including strong technical expertise in injectable dosage forms,” said Rajiv Malik, president, Mylan, in the press release. “Today's announcement is another example of how Mylan's unique global infrastructure and expertise empower other companies to expand their own reach by providing more patients with access to critical medicines worldwide."